COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy

What this Trial Is About

Researchers are developing a real-time epidemiology registry to evaluate COVID-19 risk assessment scores by recording symptoms, biomarkers, chronic illnesses, and mental health using digital tools like wearables and mobile apps. The study aims to explore variations in COVID-19 presentation among both PCR positive and negative individuals and identify factors predicting disease severity and post-COVID-19 complications. In Phase 2, 2,700 COVID-19 positive subjects will be studied to compare the effects of the drug ECL-19 against placebo on hospital admission rates. The study involves using the Coromec real-time epidemiology registry and the Vitalbeat digital therapeutics platform for remote patient monitoring, integrated with mobile apps, AI chatbots, IoT wearables, and cloud computing. Participants can self-report symptoms, mental health, chronic illness status, and vital signs daily. ECL-19 is being studied as a treatment to stabilize the endothelium in early-stage COVID-19 positive subjects, aiming to reduce hospitalizations. The registry supports public health by enabling immediate reporting and risk prediction. Participants will provide daily data through the Coromec app and website, including symptom scores, vital signs like oxygen saturation and BMI, chronic illness, and mental health assessments. Researchers will monitor these measures to evaluate predictors of hospitalization and post-COVID complications. The study also assesses the treatment strategy with ECL-19. Participation may involve follow-up visits, and the data collected will help improve pandemic care and guide future public health responses.

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy